[HTML][HTML] Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model
CH Guo, WC Li, CL Peng, PC Chen, SY Lee, S Hsia - Marine Drugs, 2022 - mdpi.com
Selenium (Se) and fish oil (FO) exert anti-epidermal growth factor receptor (EGFR) action on
tumors. This study aimed to compare the anti-cancer efficacy of EGFR inhibitors (gefitinib …
tumors. This study aimed to compare the anti-cancer efficacy of EGFR inhibitors (gefitinib …
[HTML][HTML] Omega-3 fatty acid-enriched fish oil and selenium combination modulates endoplasmic reticulum stress response elements and reverses acquired gefitinib …
CH Liao, YT Tzeng, GM Lai, CL Chang, MH Hu… - Marine drugs, 2020 - mdpi.com
Non-small cell lung cancer (NSCLC)-carrying specific epidermal growth factor receptor
(EGFR) mutations can be effectively treated by a tyrosine kinase inhibitor such as gefitinib …
(EGFR) mutations can be effectively treated by a tyrosine kinase inhibitor such as gefitinib …
[HTML][HTML] Combination of fish oil and selenium enhances anticancer efficacy and targets multiple signaling pathways in anti-VEGF agent treated-TNBC tumor-bearing …
CH Guo, S Hsia, CH Chung, YC Lin, MY Shih… - Marine Drugs, 2021 - mdpi.com
Fish oil (FO) and selenium (Se) possess antiangiogenic potential in malignant tumors. This
study aimed to determine whether combination of FO and Se enhanced treatment efficacy of …
study aimed to determine whether combination of FO and Se enhanced treatment efficacy of …
[HTML][HTML] Fish Oil, Se Yeast, and micronutrient-enriched nutrition as adjuvant treatment during target therapy in a murine model of lung cancer
H Wang, S Hsia, TH Wu, CJ Wu - Marine Drugs, 2021 - mdpi.com
Despite the effectiveness of primary treatment modalities for cancer, the side effects of
treatments, medication resistance, and the deterioration of cachexia after disease …
treatments, medication resistance, and the deterioration of cachexia after disease …
[PDF][PDF] DHA increases the anti-tumor effect of gefitinib on non-small cell lung cancer with EGFR mutations in vitro
W Ren, J Wu, X Wang, Z Feng, X Shang, Z Peng - Int. J. Clin. Exp. Med, 2017 - e-century.us
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are approved as
first-line therapy for patients with non-small cell lung cancer (NSCLC) harboring EGFR …
first-line therapy for patients with non-small cell lung cancer (NSCLC) harboring EGFR …
Docosahexaenoic acid serving as sensitizing agents and gefitinib resistance revertants in EGFR targeting treatment
X Ding, L Ge, A Yan, Y Ding, J Tao, Q Liu… - OncoTargets and …, 2019 - Taylor & Francis
Objective Due to the resistance of cancer cells, chemotherapy has been severely restricted.
Docosahexaenoic acid (DHA) has been broadly identified as the chemo-sensitizing agent …
Docosahexaenoic acid (DHA) has been broadly identified as the chemo-sensitizing agent …
[HTML][HTML] Cancer cell‑specific anticancer effects of Coptis chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2
JH Kim, ES Ko, D Kim, SH Park… - International …, 2020 - spandidos-publications.com
The epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI), gefitinib, is an
effective therapeutic drug used in the treatment of non‑small cell lung cancers (NSCLCs) …
effective therapeutic drug used in the treatment of non‑small cell lung cancers (NSCLCs) …
EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
Y Jia, X Li, T Jiang, S Zhao, C Zhao… - … Journal of Cancer, 2019 - Wiley Online Library
Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD‐
1/PD‐L1) pathway have profoundly improved the clinical management of non‐small‐cell …
1/PD‐L1) pathway have profoundly improved the clinical management of non‐small‐cell …
[HTML][HTML] Dual inhibition of EGFR and IGF-1R signaling leads to enhanced antitumor efficacy against esophageal squamous cancer
J Kang, Z Guo, H Zhang, R Guo, X Zhu… - International Journal of …, 2022 - mdpi.com
Both the epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor
(IGF-1R) have been implicated in the development of cancers, and the increased expression …
(IGF-1R) have been implicated in the development of cancers, and the increased expression …
Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo
High expression of epidermal growth factor receptor (EGFR) is thought to be correlated with
cell proliferation, invasion, metastasis, resistance to chemoradiotherapy, and poor prognosis …
cell proliferation, invasion, metastasis, resistance to chemoradiotherapy, and poor prognosis …